Buflomedil Interference with the Monoclonal EMIT d. a. u. Amphetamine/ Methamphetamine Immunoassay

Clinical Chemistry and Laboratory Medicine

Volumn 35, Issue 5, 1997, Pages 369-370

  Papa, Pietro ^a   Rocchi, Loretta ^a   Mainardi, Carlo ^b   Donzelli, Giovanni ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Emergency Room   (Italy)

^c Bio Rad Laboratories Sri   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BUFLOMEDIL; DRUG METABOLITE; METHAMPHETAMINE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG URINE LEVEL; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AMPHETAMINE; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IMMUNOASSAY; MALE; METHAMPHETAMINE; MIDDLE AGED; PYRROLIDINES;

EID: 0030969178     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.1997.35.5.369     Document Type: Article

References (11)

1. Syva EMIT d. a. u. Monoclonal amphetamine/methamphetamine assay user's manual, 1992, Palo Alto, Ca, Syva Co.
2. Poklis A, Hall KV, Still J, Binder SR. Ranitidine interference with the monoclonal EMIT d. a. u. amphetamine/methamphetamine immunoassay. J Anal Toxicol 1991: 15: 101-103.
3. Grinstead GF. Ranitidine and high concentrations of phenylpropanolamine cross-react in the EMIT monoclonal amphetamine/ methamphetamine assay. Clin Chem 1989: 35: 1998-9.
4. Binder SR, Regalia M, Biaggi-McEachern M, Mazhar M. Automated liquid Chromatographie analysis of drugs in urine by on-line sample cleanup and isocratic multicolumn separation. J Chromatogr 1989: 473: 325-341.
5. Binder SR, Regalia M, Sivrinovsky G. Toxicological screening by liquid chromatography. Trends Anal Chem 1989: 8: 362-367.
6. Clissold SP, Lynch S, Sorkin E. Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs 1987: 33: 430-460.
7. Gunter-Remy U, Weber E, Law G, Chion WL, Mann W, Aynilian GH. The clinical pharmacokinetics of buflomedil in normal subjects after intravenous and oral administration. Eur J Clin Pharmacol 1981: 20: 459-463.
8. Rey E, Barrier G, d'Athis P, Delanture D, Richard MO, Lizzin JP, et al. Pharmacokinetics of buflomedil after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 1980: 18: 437-441.
9. Athanaselis S, Maravelias C, Michalodimitrakis M, Koutselinis A. Buflomedil concentrations in blood and viscera in a case of fatal intoxication. Clin Chem 1984: 30: 157.
10. Martinez-Sierra R, Lara B, Torres A. Buflomedil intoxication: the little-known risk. Clin Toxicol 1992: 30 (2): 305-308.
11. Otmane-Telba M, Gury B, Paulien R, Feret J, Novailhat F. Toxicite'neurologique reversible du surdosage au buflomedil. Presse Med 1985: 14: 286.